DRR168531
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.440
- ANDROGEN_RESPONSE+0.330
- ANGIOGENESIS+0.320
- UV_RESPONSE_DN+0.320
- MYC_TARGETS_V1+0.310
- TGF_BETA_SIGNALING+0.300
- KRAS_SIGNALING_UP+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- WNT_BETA_CATENIN_SIGNALING+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.340
- IL6_JAK_STAT3_SIGNALING-0.270
- MYC_TARGETS_V2-0.230
- DNA_REPAIR-0.220
- ALLOGRAFT_REJECTION-0.200
- E2F_TARGETS-0.170
- MYOGENESIS-0.140
- XENOBIOTIC_METABOLISM-0.130
- BILE_ACID_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195651 | — | — | 0.767 |
| 2 | 20020076.Her2HRpos | — | C | 0.745 |
| 3 | SRR25617938 | — | B | 0.736 |
| 4 | SRR25617942 | — | C | 0.726 |
| 5 | MBCProject_0067_T1_RNA | — | A | 0.725 |
| 6 | 5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418 | — | — | 0.723 |
| 7 | TCGA-CN-4731-01A-01R-1436-07 | — | — | 0.719 |
| 8 | a7bda5b9-9c95-4f90-bab6-10ab15ee2b48 | — | — | 0.714 |
| 9 | R420 | — | — | 0.703 |
| 10 | R140 | — | — | 0.699 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |